Clinical Study
Risk of Falls in Parkinson’s Disease: A Cross-Sectional Study of 160 Patients
Table 2
Functional tests, gait parameters, and drug treatments a.
| | All patients () | Nonfallers () | Fallers () | Testb | value |
| | Tinetti | | | | | | | Balance | 10.9 (5.7) | 13.4 (3.9) | 7.1 (6.0) | 1 | <0.001 | | Gait | 8.6 (4,6) | 10.3 (3.2) | 5.8 (5.2) | 1 | <0.001 | | Total | 19.5 (10.2) | 23.7 (7.0) | 12.9 (11.0) | 1 | <0.001 | | Timed up and go (s) | 11.4 (8.0) | 10.7 (7.9) | 13.1 (8.1) | 1 | 0.004 | | Velocity (m/s) | 1.17 (0.31) | 1.19 (0.30) | 1.10 (0.32) | 1 | 0.293 | | Step length (m) | 0.77 (0.20) | 0.79 (0,24) | 0.69 (0.22) | 1 | 0.093 | | Cadence (steps/s) | 1.55 (0.70) | 1.52 (0.23) | 1.61 (0.41) | 1 | 0.253 | | Levodopa use (, %) | 139 (86.8) | 84 (85.7) | 55 (88.7) | 2 | 0.639 | | Levodopa dose (mg/d) | 557.8 (254.1) | 504.1 (208.3) | 638.7 (295.8) | 1 | 0.005 | | Dopamine agonist use (, %) | 98 (61.2) | 58 (59.2) | 40 (64.5) | 2 | 0.511 | | MAOB-I use (, %) | 49 (30.6) | 29 (29.5) | 20 (32.2) | 2 | 0.728 | | COMT-I use (, %) | 25 (15.6) | 10 (10.2) | 15 (24.2) | 2 | 0.025 | | Amantadine use (, %) | 13 (8,1) | 5 (5.1) | 8 (12.9) | 2 | 0.134 | | Anticholinergic use (, %) | 2 (1.2) | 2 (2.0) | 0 | | | | Polytherapy (, %) | 83 (51.8) | 49 (50.0) | 34 (54.8) | 2 | 0.649 | | Benzodiazepine use (, %) | 22 (13.7) | 12 (12.2) | 10 (16.1) | 2 | 0.490 | | Antidepressant use (, %) | 18 (11.2) | 11 (11.2) | 7 (11.3) | 2 | 1.000 | | Neuroleptic use (, %) | 8 (5.0) | 1 (1.0) | 7 (11.3) | 2 | 0.006 | | Cholinesterase inhibitor use (, %) | 7 (4.3) | 0 | 7 (11.3) | 2 | 0.001 |
|
|
Abbreviations. MAOBI: inhibitor of monoamine oxidase B; COMTI: inhibitor of catechol-O-methyl transferase.
aData are mean(SD), absolute numbers, or percentage.
bTest 1 = independent samples -test; test test.
|
